`______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________________
`
`APPLE INC.,
`Petitioner
`
`v.
`
`SMARTFLASH LLC,
`Patent Owner
`______________________
`
`Case CBM2015-00124
`Patent 7,942,317
`______________________
`
`Before the Honorable JENNIFER S. BISK, RAMA G. ELLURU, JEREMY M.
`PLENZLER, and MATTHEW R. CLEMENTS, Administrative Patent Judges.
`
`
`PETITIONER APPLE INC.’S OPPOSITION TO
`PATENT OWNER’S MOTION TO EXCLUDE UNDER 37 C.F.R. § 42.64(c)
`
`
`
`
`
`
`
`
`TABLE OF CONTENTS
`
`CBM2015-00124
`Patent 7,942,317
`
`
`
`I. THE BOARD SHOULD NOT EXCLUDE EXHIBITS 1002 AND 1034 ........ 2
`II. THE BOARD SHOULD NOT EXCLUDE EXHIBITS 1003-06,
`1009-16, 1019, 1021-26, AND 1029-33 ............................................................ 4
`III. THE BOARD SHOULD NOT EXCLUDE EXHIBIT 1017 ............................. 9
`IV. THE BOARD SHOULD NOT EXCLUDE EXHIBIT 1028 ........................... 13
`
`
`
`
`
`CBM2015-00124
`Patent 7,942,317
`
`
`In response to Patent Owner’s (“PO”) Motion to Exclude (“Mot.”, Pap. 24),
`
`Petitioner respectfully submits that the Board, sitting as a non-jury tribunal with
`
`administrative expertise, is well-positioned to determine and assign appropriate
`
`weight to the evidence presented here, without resorting to formal exclusion that
`
`might later be held reversible error. See, e.g., S.E.C. v. Guenthner, 395 F. Supp. 2d
`
`835, 842 n.3 (D. Neb. 2005); Builders Steel Co. v. Comm’r of Internal Revenue,
`
`179 F.2d 377, 379 (8th Cir. 1950) (vacating Tax Court decision for exclusion of
`
`competent, material evidence); Donnelly Garment Co. v. Nat’l Labor Relations
`
`Bd., 123 F.2d 215, 224 (8th Cir. 1941) (NLRB’s refusal to receive testimonial evi-
`
`dence was denial of due process). See also, e.g., Samuel H. Moss, Inc. v. F.T.C.,
`
`148 F.2d 378, 380 (2d Cir. 1945), cert. denied, 326 U.S. 734 (1945) (“Even in
`
`criminal trials to a jury it is better, nine times out of ten, to admit, than to exclude, .
`
`. . and in such proceedings as these the only conceivable interest that can suffer by
`
`admitting any evidence is the time lost, which is seldom as much as that inevitably
`
`lost by idle bickering about irrelevancy or incompetence.”). But even under strict
`
`application of the Rules of Evidence, cf. 77 Fed. Reg. 48,612, 48,616 (Aug. 14,
`
`2012) (“42.5(a) and (b) permit administrative patent judges wide latitude in admin-
`
`istering the proceedings to balance the ideal of precise rules against the need for
`
`flexibility to achieve reasonably fast, inexpensive, and fair proceedings”), Petition-
`
`er’s evidence here is entirely proper while PO’s objections—many of which have
`1
`
`
`
`
`
`CBM2015-00124
`Patent 7,942,317
`already been rejected by the Board in prior proceedings on the same and related
`
`patents—are baseless.
`
`I.
`
`The Board Should Not Exclude Exhibits 1002 and 1034
`
`Petitioner did not rely on Exs. 1002 and 1034 for “evidence of the content”
`
`of the ’317 patent (cf. Mot. 2), but rather to show that PO’s and inventor Patrick
`
`Racz’s own characterizations of the subject matter of the ’317 patent support Peti-
`
`tioner’s contention (and the Board’s previous determination) that the ’317 patent
`
`relates to a financial activity or transaction and is a covered business method pa-
`
`tent. See Pap. 2 at 26. PO’s and Mr. Racz’s characterizations of the ’317 patent in
`
`another proceeding are not found in the patent itself; thus, contrary to PO’s asser-
`
`tions, Exs. 1002 and 1037 are not cumulative of the ’317 patent, and FRE 1004 is
`
`inapplicable. Indeed, as PO admits, when confronting this same argument by PO,
`
`the Board declined to exclude the same Ex. 1002 in another proceeding on a relat-
`
`ed patent. While determining whether a patent is a CBM patent requires an exami-
`
`nation of the claims, the Board found “[Patent Owner’s] characterization of the []
`
`patent in prior proceedings is relevant to the credibility of its characterization of
`
`the [same] patent in this proceeding.” Mot. 2 (citing CBM2015-00016, Pap 56 at
`
`24); see also CBM2014-00112, Pap. 48 at 24; CBM2015-00017, Pap. 46 at 22;
`
`CBM2015-00028, Pap. 44 at 25; CBM2015-00029, Pap. 43 at 27; CBM2015-
`
`00031, Pap 45 at 29; CBM2015-00032, Pap. 46 at 28-29; CBM2015-00033, Pap.
`
`
`
`2
`
`
`
`CBM2015-00124
`Patent 7,942,317
`40 at 29. The same reasoning applies here.
`
`PO again argues that “[t]here is nothing about Patent Owner’s characteriza-
`
`tion of the ‘317 Patent in this proceeding … that is contradicted by Exhibits 1002
`
`and 1034 such that the credibility of Patent Owner’s characterization is at issue”
`
`(Mot. 3). But, as the Board found in other proceedings on related patents, “Patent
`
`Owner’s argument misses the point because the credibility of Patent Owner’s char-
`
`acterization is for the Board to weigh after deciding the threshold issue of admissi-
`
`bility.” See, e.g., CBM2015-00016, Pap. 56 at 241; CBM2015-00017, Pap. 46 at
`
`22; see also CBM2015-00028, Pap. 44 at 25-26; CBM2015-00029, Pap. 43 at 27;
`
`CBM2015-00031, Pap. 45 at 29; CBM2015-00032, Pap. 46 at 29; CBM2015-
`
`00033, Pap. 40 at 29. And, contrary to PO’s claim that its characterization of the
`
`’317 patent is not at issue here (Mot. 3), PO disputes the financial nature of the
`
`’317 patent, see Pap. 5 at 39-44; Pap. 17 at 60-65. Therefore, PO’s and Mr. Racz’s
`
`admissions, which contradict PO’s arguments here, should not be excluded. See
`
`CBM2015-00016, Pap. 56 at 24 (“Patent Owner’s characterization of the [] patent
`
`in prior proceedings is relevant to Patent Owner’s contention in this proceeding
`
`that the [same] patent does not satisfy the ‘financial in nature’ requirement” for a
`
`CBM review.); CBM2015-00017, Pap. 46 at 22-23; CBM2015-00028, Pap. 44 at
`
`26; CBM2015-00029, Pap. 43 at 27; CBM2015-00031, Pap. 45 at 29; CBM2015-
`
`1 All emphasis herein is added unless otherwise indicated.
`
`
`
`3
`
`
`
`CBM2015-00124
`Patent 7,942,317
`00032, Pap. 46 at 29; CBM2015-00033, Pap. 40 at 29.
`
`Further, PO is wrong that Exs. 1002 and 1034 do not “appear to make a fact
`
`of consequence in determining this action” merely because the Kelly Declaration
`
`(Ex. 1017) and the Board’s Institution Decision (Pap. 7) do not cite them. Mot. 3-
`
`4. As PO admits, both Exs. 1002 and 1034 are cited in the Petition (Pap. 2) “as
`
`support for the ‘317 Patent being ‘financial in nature’ and thus CBM review eligi-
`
`ble.” Mot. 2 (citing Petition at 24-27). And, Ex. 1034 is also cited in Petitioner’s
`
`Reply (Pap. 21) to show that various elements of the challenged claims are not in-
`
`ventive. See Pap. 21 at 10, 12. Because Exs. 1002 and 1034 reflect facts of conse-
`
`quence in determining this action under FRE 401, they are relevant and should not
`
`be excluded.
`
`II.
`
`The Board Should Not Exclude Exhibits 1003-06, 1009-16, 1019, 1021-
`26, and 1029-33
`
`Contrary to PO’s assertions, Exs. 1003-06, 1009-16, 1019, 1021-26, and
`
`1029-33 (“Prior Art Exhibits”) are relevant to the Board’s § 101 analysis. As PO
`
`admits, when confronting the same argument from PO, the Board declined to ex-
`
`clude similar exhibits in another proceeding on a related patent because “these ex-
`
`hibits are relevant to the state of the art—whether the technical limitations of the
`
`challenged claim were well-known, routine, and conventional—and thus, to our §
`
`101 analysis.” Mot. 6 (citing CBM2015-00016, Pap. 56 at 26); see also, e.g., Alice
`
`Corp. Pty. Ltd. v. CLS Bank Int’l, 134 S. Ct. 2347, 2357, 2359 (2014); YYZ, LLC v.
`
`
`
`4
`
`
`
`CBM2015-00124
`Patent 7,942,317
`Hewlett-Packard Co., No. 13-136-SLR, 2015 WL 5886176, at *8 (D. Del. Oct. 8,
`
`2015) (“Although the § 101 inquiry is focused on the claim language, extrinsic ev-
`
`idence [, such as prior art,] may be helpful in terms of understanding the state of
`
`the art . . . , and whether the problem to which the patent was directed is solved us-
`
`ing computer technology in unconventional ways.”); CBM2015-00017, Pap. 46 at
`
`24; CBM2015-00028, Pap. 44 at 27; CBM2015-00029, Pap. 43 at 29; CBM2015-
`
`00031, Pap. 45 at 31; CBM2015-00032, Pap. 46 at 30; CBM2015-00033, Pap. 40
`
`at 31; CBM2014-00190, Pap. 47 at 29; CBM2014-00192, Pap. 45 at 26;
`
`CBM2014-00193, Pap. 45 at 26; CBM2014-00194, Pap. 51 at 28; cf. Versata Dev.
`
`Grp., Inc. v. SAP Am., Inc., 793 F.3d 1306, 1334, 1336 (Fed. Cir. 2015) (affirming
`
`Board’s reliance on petitioner’s expert in determining that claimed steps were well-
`
`known, routine, and conventional and Board’s finding that “claims at issue do not
`
`recite any improvement in computer technology”). Nothing in this proceeding
`
`should change that outcome. Indeed, both the Petition and the Kelly Declaration
`
`rely on Prior Art Exhibits to show (1) the state of the art, (2) that the basic concept
`
`of controlling access based on payment and/or rules—to which the challenged
`
`claims are directed—was well-known in the prior art, and/or (3) that the elements
`
`disclosed by the challenged claims were well-known, routine, and conventional.
`
`See, e.g., Pap. 2 at 7-20 (Overview of Field of the Claimed Invention), 43, 48, 53,
`
`55, 57-58, 60-67 (citing Prior Art Exhibits); Ex. 1017 ¶¶ 23-73 (State of the Art),
`
`
`
`5
`
`
`
`CBM2015-00124
`Patent 7,942,317
`75-78, 80-82 (citing Prior Art Exhibits). And, there is no requirement that the
`
`Board’s Institution Decision cite every piece of potentially relevant evidence in its
`
`Institution Decisions for the evidence to “make a fact of consequence in determin-
`
`ing this action,” as PO contends. Mot. 5. Further, in its final written decisions in
`
`prior proceedings on related patents, the Board cited prior art references in deter-
`
`mining patent eligibility. CBM2015-00016, Pap. 56 at 13 (relying on prior art to
`
`show concepts claimed in related patent were known); CBM2015-00017, Pap. 46
`
`at 17-18 (same); CBM2015-00028, Pap. 44 at 19 (same); CBM2015-00029, Pap.
`
`43 at 21 (same); CBM2015-00031, Pap. 45 at 22 (same); CBM2015-00032, Pap.
`
`46 at 22-23 (same); CBM2015-00033, Pap. 40 at 22-23 (same); CBM2014-00190,
`
`Pap. 47 at 19-20 (same); CBM2014-00192, Pap. 45 at 13-14 (same); CBM2014-
`
`00193, Pap. 45 at 17 (same); CBM2014-00194, Pap. 51 at 19 (same).
`
`PO also puts the cart before the horse in arguing that the Prior Art Exhibits
`
`are not relevant because “[w]hether the technical limitations of the challenged
`
`claim were well-known, routine, and conventional is only relevant after finding
`
`that a claim is directed to an abstract idea and ... [h]ere, the claims at issue are not
`
`directed to an abstract idea.” (Mot. 6-7). It would be nonsensical to exclude the
`
`Prior Art Exhibits before the Board determines whether it needs to perform the
`
`second step of the Mayo analysis, as PO urges. This is particularly so in light of the
`
`fact that the Board has already determined that a multitude of related claims are di-
`
`
`
`6
`
`
`
`CBM2015-00124
`Patent 7,942,317
`rected to an abstract idea. See CBM2015-00016, Pap. 56 at 8-9; CBM2015-00017,
`
`Pap. 46 at 7-9; CBM2015-00028, Pap. 44 at 8-10; CBM2015-00029, Pap. 43 at 9-
`
`11; CBM2015-00031, Pap. 45 at 11-13; CBM2015-00032, Pap. 46 at 11-13;
`
`CBM2015-00033, Pap. 40 at 11-13; CBM2014-00190, Pap. 47 at 8-10; CBM2014-
`
`00192, Pap. 45 at 7-9; CBM2014-00193, Pap. 45 at 8-9; CBM2014-00194, Pap. 51
`
`at 8-9. The Prior Art Exhibits are unquestionably relevant to the § 101 analysis;
`
`there is no basis to exclude them.
`
`Moreover, in arguing that the Prior Art Exhibits should be excluded, PO im-
`
`properly raises for the first time a new substantive argument regarding the Federal
`
`Circuit’s recent decision in Enfish, LLC v. Microsoft Corp., No. 2015-1244, 2016
`
`WL 2756255 (Fed. Cir. May 12, 2016). See Mot. 6-7; Motorola Mobility LLC v.
`
`Intellectual Ventures I LLC, IPR2014-00501, Pap. 48 at 31 (“A motion to exclude
`
`is neither a substantive sur-reply, nor a proper vehicle for arguing whether a reply
`
`or supporting evidence is of appropriate scope.”). Even if this analysis were
`
`properly presented in this context, it is wrong, and ignores more analogous cases,
`
`such as In re TLI Communications LLC Patent Litigation, No. 2015-1372, 2016
`
`WL 2865693 (Fed. Cir. May 17, 2016) and Ultramercial, Inc. v. Hulu, LLC, 772
`
`F.3d 709 (Fed. Cir. 2014). Indeed, contrary to PO’s argument (Mot. 6-7), the chal-
`
`lenged claims here are not “directed to an improvement to computer functionality”
`
`like the “innovative,” “self-referential table for a computer database” claimed in
`
`
`
`7
`
`
`
`CBM2015-00124
`Patent 7,942,317
`Enfish. 2016 WL 2756255, at *1, *5. Rather, the challenged claims are like the
`
`claims held ineligible in TLI—another recent decision noticeably absent from PO’s
`
`Motion—and Ultramercial. In TLI, the Federal Circuit distinguished the Enfish
`
`claims based on the fact that the TLI claims, like the challenged claims here, “are
`
`directed to the use of conventional or generic technology in a nascent but well-
`
`known environment.” TLI, 2016 WL 2865693, at *3. Like the TLI claims, and
`
`like related claims already found patent ineligible, the challenged claims “perform[]
`
`generic computer functions such as storing, receiving, and extracting data” using
`
`“physical components” (e.g., wireless interface, non-volatile memory, processor,
`
`display) that “behave exactly as expected according to their ordinary use” and
`
`“merely provide a generic environment in which to carry out the abstract idea” of
`
`controlling access to content based on payment and/or rules. Id. at *3, *4, *7; see,
`
`e.g., Pap. 2 at 48, 50-67; Pap. 21 at 6-12; see also CBM2015-00016, Pap. 56 at 9-
`
`17; CBM2015-00017, Pap. 46 at 9-18; CBM2015-00028, Pap. 44 at 10-20;
`
`CBM2015-00029, Pap. 43 at 11-21; CBM2015-00031, Pap. 45 at 13-23;
`
`CBM2015-00032, Pap. 46 at 13-23; CBM2015-00033, Pap. 40 at 13-23;
`
`CBM2014-00190, Pap. 47 at 10-20; CBM2014-00192, Pap. 45 at 9-18; CBM2014-
`
`00193, Pap. 45 at 9-17; CBM2014-00194, Pap. 51 at 10-20; cf. Enfish, 2016 WL
`
`2756255, at *6 (“[T]he self-referential table functions differently than conventional
`
`database structures.”). And, like other related patent claims that the Board already
`
`
`
`8
`
`
`
`CBM2015-00124
`Patent 7,942,317
`determined are ineligible, the challenged claims here “are like the claims at issue in
`
`Ultramercial,” which “condition and control access based on viewing an adver-
`
`tisement.” See, e.g., CBM2015-00016, Pap. 56 at 17. “Similar to the claims in Ul-
`
`tramercial, the majority of limitations in the challenged claims comprise this ab-
`
`stract concept of conditioning and controlling access to data.” Id.; see also
`
`CBM2015-00017, Pap. 46 at 16; CBM2015-00028, Pap. 44 at 17; CBM2015-
`
`00029, Pap. 43 at 19; CBM2015-00031, Pap. 45 at 20-21; CBM2015-00032, Pap.
`
`46 at 21; CBM2015-00033, Pap. 40 at 20-21; CBM2014-00190, Pap. 47 at 17-18;
`
`CBM2014-00192, Pap. 45 at 17-18; CBM2014-00193, Pap. 45 at 15-16;
`
`CBM2014-00194, Pap. 51 at 17. Read together, Enfish, TLI, and Ultramercial fur-
`
`ther confirm that the challenged claims are ineligible.
`
`III. The Board Should Not Exclude Exhibit 1017
`
`PO does not dispute Dr. Kelly’s qualifications or competence, and instead
`
`seeks to exclude the Kelly Declaration based on three meritless arguments: (1) his
`
`opinions are not legal opinions and §§ 101 and 112 are “purely legal issues” (Mot.
`
`7-9), (2) he did not “test the method” he used “against known [§ 101] decisions” to
`
`determine a “false [positive/negative] rate” (Mot. 10-11), and (3) his opinions “re-
`
`flect an analysis that looks for an inventive concept over the prior art, rather than
`
`over the abstract idea itself” (Mot. 11-12 (emph. orig.)).
`
`First, the Board has already rejected PO’s argument that expert opinions are
`
`
`
`9
`
`
`
`CBM2015-00124
`Patent 7,942,317
`not relevant to § 101 issues in other proceedings on related patents, finding that an
`
`expert’s opinions on § 101 “relate to the underlying factual issues related to patent
`
`eligibility.” CBM2015-00016, Pap. 56 at 28; CBM2015-00017, Pap. 46 at 26;
`
`CBM2015-00028, Pap. 44 at 30-31; CBM2015-00029, Pap. 43 at 31-32;
`
`CBM2015-00031, Pap. 45 at 33-34; CBM2015-00032, Pap. 46 at 32-33;
`
`CBM2015-00033, Pap. 40 at 33-34; CBM2014-00190, Pap. 47 at 26-27;
`
`CBM2014-00192, Pap. 45 at 24; CBM2014-00193, Pap. 45 at 24; CBM2014-
`
`00194, Pap. 51 at 26-27; see also Accenture Global Servs., GmbH v. Guidewire
`
`Software, Inc., 728 F.3d 1336, 1340-41 (Fed. Cir. 2013) (“Patent eligibility under §
`
`101 presents an issue of law . . . . [that] may contain underlying factual issues.”);
`
`Arrhythmia Research Tech., Inc. v. Corazonix Corp., 958 F.2d 1053, 1055-56
`
`(Fed. Cir. 1992) (“[D]etermination of [statutory subject matter] may require find-
`
`ings of underlying facts specific to the particular subject matter and its mode of
`
`claiming.”); YYZ, 2015 WL 5886176, at *8; CBM2015-00017, Pap. 46 at 14-15
`
`(citing expert testimony in finding related claims are not directed to an Internet-
`
`specific problem); CBM2015-00028, Pap. 44 at 16 (same); CBM2015-00029, Pap.
`
`43 at 17-18 (same); CBM2015-00031, Pap. 45 at 19 (same); CBM2015-00032,
`
`Pap. 46 at 19-20 (same); CBM2015-00033, Pap. 40 at 19-20 (same); CBM2014-
`
`00190, Pap. 47 at 11-12 (citing expert testimony in finding related claims have no
`
`inventive concept); CBM2014-00192, Pap. 45 at 9 (same); CBM2014-00193, Pap.
`
`
`
`10
`
`
`
`CBM2015-00124
`Patent 7,942,317
`45 at 9 (same); CBM2014-00194, Pap. 51 at 10-11 (same); cf. Versata, 793 F.3d at
`
`1334 (affirming Board’s reliance on petitioner’s expert over patent owner’s expert
`
`in determining claimed steps were well-known, routine, and conventional). And
`
`there is no dispute that Dr. Kelly is competent to opine on the factual issues. Cf.
`
`Mot. 7-12. Similarly, Dr. Kelly’s testimony related to § 112 should not be exclud-
`
`ed “[b]ecause this testimony is related to how one skilled in the art would under-
`
`stand certain claim limitations” (CBM2015-00016, Pap. 56 at 28), which is un-
`
`questionably relevant to § 112 determinations. See Nautilus, Inc. v. Biosig Instru-
`
`ments, Inc., 134 S. Ct. 2120, 2124 (2014) (“[W]e hold that a patent is invalid for
`
`indefiniteness if its claims … fail to inform, with reasonable certainty, those skilled
`
`in the art about the scope of the invention.”); see also CBM2015-00016, Pap. 56 at
`
`22 (relying on expert testimony in determining related patent claim indefinite un-
`
`der 35 U.S.C. § 112). Because Dr. Kelly’s opinions relate to the factual issues that
`
`underlie the §§ 101 and 112 inquiries, 37 C.F.R. § 42.65 is inapplicable, and his
`
`opinions should not be excluded.
`
`Second, there is no support for PO’s argument—indeed, PO cites none—that
`
`experts, such as Dr. Kelly—who is an engineer, not an attorney—are required to
`
`review legal opinions on § 101 or compare the challenged claims to claims ad-
`
`dressed in such legal opinions to determine a false positive or negative rate. Dr.
`
`Kelly analyzed the facts and information relevant to the two-step analysis required
`
`
`
`11
`
`
`
`CBM2015-00124
`Patent 7,942,317
`by Mayo. See, e.g., Pap. 21 at 11, 20-21.
`
`Third, PO misapprehends the law in arguing that the Kelly Declaration
`
`should be excluded because Dr. Kelly looks for an inventive concept over the prior
`
`art, rather than over the abstract idea itself. The relevant inquiry is not, as PO sug-
`
`gests, whether a claim’s “additional features” are inventive over the abstract idea,
`
`but rather whether they provide an inventive concept despite that the claim is di-
`
`rected to an abstract idea. The required determination is whether the elements left
`
`after removing the abstract idea (i.e., “additional features”) amount to an “in-
`
`ventive concept,” such that they “‘transform the nature of the claim’ into a patent-
`
`eligible application.” Alice, 134 S. Ct. at 2355, 2357; see also Mayo Collaborative
`
`Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1304 (2012) (distinguishing §
`
`101 inquiry from §§ 102 and 103). As stated above, Dr. Kelly performed the cor-
`
`rect analysis required by Mayo. See, e.g., Pap. 21 at 11, 20-21.
`
`Finally, PO misses the mark in seeking to exclude the portions of the Kelly
`
`Declaration that “rel[y] upon an exhibit that is objected to herein for the reasons set
`
`forth in those objections.” Mot. 12. The only exhibits that are both cited in the
`
`Kelly Declaration and objected to by PO are the Prior Art Exhibits discussed in §
`
`II, supra. However, as detailed in § II, the Kelly Declaration’s description of the
`
`art at the relevant time is clearly relevant to the § 101 inquiry. For the same rea-
`
`sons the Prior Art Exhibits are relevant, expert analyses of those exhibits are rele-
`
`
`
`12
`
`
`
`CBM2015-00124
`Patent 7,942,317
`vant under FRE 401 and should not be excluded. See, e.g., CBM2015-00016, Pap.
`
`56 at 27-28 (“Because this review is under § 101, analyses of the state of the prior
`
`art … is relevant to the second prong of the Alice and Mayo inquiry.”). Dr. Kelly’s
`
`unrebutted conclusions regarding what would be considered well-known, routine,
`
`and conventional (see, e.g., Ex. 1017 §§ VI and VII) are entitled to weight.
`
`IV. The Board Should Not Exclude Exhibit 1028
`
`Contrary to PO’s argument (Mot. 12), the sworn admissions of its expert in
`
`prior proceedings regarding what was well-known at the time of the challenged pa-
`
`tents are relevant to the § 101 inquiry. PO does not dispute that Dr. Katz would
`
`have qualified as a person of ordinary skill in the art in the relevant time period,
`
`and, indeed, proffered Dr. Katz as an expert with the knowledge of a person of or-
`
`dinary skill in the art in prior proceedings on the same and related patents. There-
`
`fore, Dr. Katz’s testimony, which provides further evidence that a person of ordi-
`
`nary skill in the art would have understood various elements of the challenged
`
`claims to be well-known, routine, and conventional in the relevant time period, is
`
`highly relevant and should not be excluded under FRE 401.
`
`Further, PO’s hearsay argument is inapplicable. The cited portions of Ex.
`
`1028 are not hearsay at least because they are party admissions under FRE
`
`801(d)(2)(C)2 and 801(d)(2)(D).3 There is no dispute that Dr. Katz was retained by
`
`2 Under FRE 801(d)(2)(C), a statement is not hearsay where it “is offered against
`
`
`
`13
`
`
`
`CBM2015-00124
`Patent 7,942,317
`PO in a prior proceeding involving the same parties to provide expert opinion on
`
`the patentability of the same ‘317 patent, including related questions regarding pri-
`
`or art and one of ordinary skill, or that he was authorized by PO to provide his
`
`sworn declaration and deposition testimony on PO’s behalf.4 PO unquestionably
`
`an opposing party and . . . was made by a person whom the party authorized to
`
`make a statement on the subject.” See, e.g., Samaritan Health Ctr. v. Simplicity
`
`Health Care Plan, 459 F. Supp. 2d 786, 799 (E.D. Wis. 2006) (“[B]ecause First
`
`Health proffers its opponent’s expert report against that opponent, the report can be
`
`considered an admission by a party-opponent, which falls outside the hearsay defi-
`
`nition. Fed.R.Evid. 801(d).”).
`
`3 Under FRE 801(d)(2)(D), a statement is not hearsay where it “was made by the
`
`party’s agent or employee on a matter within the scope of that relationship and
`
`while it existed.”
`
`4 In addition, the Board may consider, as an analogous situation, that the Federal
`
`Rules of Civil Procedure would allow for Dr. Katz’s prior testimony to be admissi-
`
`ble in a court proceeding under Rule 32, which provides for the admission of a
`
`deposition taken in a prior matter where the parties and subject matter of the in-
`
`stant matter are the same as involved in the prior matter, as is true here. See FRCP
`
`32(a)(1), 32(a)(4)(B), 32(a)(8); see also, e.g., Hub v. Sun Valley Co., 682 F.2d 776,
`
`778 (9th Cir. 1982) (Rule 32(a)(8) requirements should be “construed liberally.”).
`
`
`
`14
`
`
`
`CBM2015-00124
`Patent 7,942,317
`had the opportunity and motive at the deposition to cross-examine Dr. Katz, its
`
`own expert providing sworn testimony on its behalf, on those topics. Further, PO
`
`has been on notice since the filing of the Petition that Petitioner intended to rely on
`
`the admissions of Dr. Katz, but chose not to seek deposition or otherwise take dis-
`
`covery of Dr. Katz in this proceeding. And, even if Dr. Katz’s admissions were
`
`hearsay (they are not), they are subject to the residual hearsay exception under
`
`FRE 807.5 Although other evidence demonstrates that the challenged claims are
`
`not inventive, Dr. Katz’s admissions are highly probative, given that PO—who
`
`hired and proffered Dr. Katz as an expert on these subjects—cannot credibly deny
`
`them. And, as noted above, Dr. Katz’s sworn testimony is certainly sufficiently
`
`trustworthy and its admission would serve the interests of justice.
`
`For the foregoing reasons, PO’s most recent attempts to exclude this rele-
`
`vant, admissible evidence should again be rejected.
`
`
`
`
`
`June 27, 2016
`
`
`
`
`5 FRE 807 provides that hearsay may be admitted even where it is not specifically
`
`Respectfully submitted,
`By /J. Steven Baughman/
`J. Steven Baughman, Lead Counsel
`
`covered by a hearsay exception where it is sufficiently trustworthy, offered as evi-
`
`dence of material fact, more probative on that point than other evidence that can be
`
`obtained through reasonable efforts, and where admitting it will best serve the pur-
`
`poses of the FRE and the interests of justice.
`
`
`
`15
`
`
`
`CBM2015-00124
`Patent 7,942,317
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing PETITIONER
`
`APPLE INC.’S OPPOSITION TO PATENT OWNER’S MOTION TO EX-
`
`CLUDE was served on June 27, 2016, to the following counsel via e-mail, pursu-
`
`ant to the parties’ agreement concerning service:
`
`Michael R. Casey
`Wayne M. Helge
`DAVIDSON BERQUIST JACKSON & GOWDEY LLP
`8300 Greensboro Dr., Suite 500
`McLean, VA 22102
`Telephone: (571) 765-7700
`Facsimile: (571) 765-7200
`mcasey@dbjg.com
`whelge@davidsonberquist.com
`SmartFlash-CBM@dbjg.com
`
`Attorneys for Patent Owner Smartflash LLC
`
`/s/ Sharon Lee
`Sharon Lee
`
`
`
`ROPES & GRAY LLP
`
`16